DPC AGGIORNATO AL 25/04/2011 PER SPECIALITA'
|
|
|
- Bryce Atkinson
- 8 years ago
- Views:
Transcription
1 DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' ABILIFY CPR. 0MG. N0AX2 ARIPIPRAZOLO ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO ABILIFY CPR. ORODISP. 0MG. N0AX2 ARIPIPRAZOLO ABILIFY CPR. ORODISP. MG. N0AX2 ARIPIPRAZOLO ABILIFY GTT N0AX2 ARIPIPRAZOLO ACTOS CPR MG. A0BG03 PIOGLITAZONE ACTOS CPR MG. A0BG03 PIOGLITAZONE ADVAGRAF cps ril prol 0, mg L04AD02 TACROLIMUS 2/04/ ADVAGRAF cps ril prol 3 mg L04AD02 TACROLIMUS 2/04/ ADVAGRAF cps ril prol mg L04AD02 TACROLIMUS 2/04/ ADVAGRAF cps ril prol mg L04AD02 TACROLIMUS 2/04/ ALDARA CREMA % 2 BUST 20MG. D06BB0 IMIQUIMOD ALFAFERONE F ML. L03AB0 TERFERONE ALFA NATURALE ALFAFERONE F ML. L03AB0 TERFERONE ALFA NATURALE ALFAFERONE F ML. L03AB0 TERFERONE ALFA NATURALE ANDRIOL cpr 40 mg G03BA03 TESTOSTERONE UNDECANOATO 2/04/ ARANESP 0 mcg. sir. prer. sc. ev ARANESP 20 mcg. sir. prer. sc. ev ARANESP 20 mcg. Penna sc. ev ARANESP mcg. sir. prer. sc. ev ARANESP 40 mcg. Penna sc. ev ARANESP 40 mcg. sir. prer. sc. ev ARANESP 0 mcg. sir. prer. sc. ev ARANESP mcg. Penna sc. ev ARANESP mcg. sir. prer. sc. ev ARANESP 80 mcg. Penna sc. ev ARANESP 80 mcg. sir. prer. sc. ev ARANESP 00 mcg. Penna sc. ev ARANESP 00 mcg. sir. prer. sc. ev ARANESP 0 mcg. Penna sc. ev ARANESP 0 mcg. sir. prer. sc. ev ARANESP 0 mcg. sir. prer. sc. ev ARANESP 0 mcg. Penna sc. ev ARANESP 00 mcg. Penna sc. ev ARANESP 00 mcg. sir. prer. sc. ev ARAVA 3CPR. RIV. 00MG. L04AA3 LEFLUNOMIDE ARAVA FLAC. CPR. RIV. 20MG. L04AA3 LEFLUNOMIDE ARICEPT CPR. RIV. MG. N06DA02 DONEZEPIL ARICEPT CPR. RIV. 0MG. N06DA02 DONEZEPIL ARICEPT*CPR RIV MG ORODISP N06DA02 DONEZEPIL ARICEPT*CPR RIV 0 MG ORODISP N06DA02 DONEZEPIL BICALUTAMIDE TEVA CPR. RIV. 0 MG. L02BB03 BICALUTAMIDE BICALUTAMIDE TEVA CPR. RIV. 0 MG. L02BB03 BICALUTAMIDE BOCRIT.000 UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT.000 UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE 2/04/ BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE 2/04/ BOCRIT.000 UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE 2/04/ BOCRIT UI sir prer sc ev B03XA0 EPOETA ALFA BIOSIMILARE 2/04/ Pagina
2 DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' BYETTA PENNA,2 ml./ mcg. A0BH04 EXENATIDE BYETTA PENNA 2,4 ml./0 mcg. A0BH04 EXENATIDE CARNITENE 2 gr fl os A6AA0 LEVO CARNITA CLORIDRATO 0 2/04/ CERTICAN cpr 0,2mg L04AA8 EVEROLIMUS 2/04/ CERTICAN cpr 0,7mg L04AA8 EVEROLIMUS 2/04/ CERTICAN cpr disp 0,2mg L04AA8 EVEROLIMUS 2/04/ COMPETACT CPR mg mg. A0BD0 PIOGLITAZONE/METFORMA CLORIDRATO COMTAN 00CPR RIV 200 MG. N04BX02 ENTACAPONE DECAPEPTYL FL. 3,7MG.+2ML.+ SIR. L02AE04 TRIPTORELA DECAPEPTYL FL.,2MG.+2ML.+ SIR. L02AE04 TRIPTORELA EFIENT cpr riv mg B0AC22 PRASUGREL 2/04/ EFIENT cpr riv 0 mg B0AC22 PRASUGREL 2/04/ ELIGARD 22, mg. kit L02AE02 LEUPRORELA ACETATO ELIGARD 7, mg. Kit L02AE02 LEUPRORELA EMOST IM EV SC 0F. 20MCG. ML. H0AB02 DESMOPRESSA ENANTONE IM SC FL.+ SIR.,2MG./2ML. L02AE02 LEUPRORELA ENANTONE IM SC FL.+ SIR.3,7MG./2ML. L02AE02 LEUPRORELA EPORATIO U.I. sir. prer. sc. ev. B03XA0 EPOETA TETA 2/04/ EPORATIO U.I. sir. prer. sc. ev. B03XA0 EPOETA TETA 2/04/ EPORATIO.000 U.I. sir. prer. sc. ev. B03XA0 EPOETA TETA 2/04/ EPREX.000 U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX.000 U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EPREX U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA ALFA EUCREAS cps 0mg/000mg A0BD08 VIDAGLIPT + METFORMA 2/04/ EUCREAS cps 0mg/80mg A0BD08 VIDAGLIPT + METFORMA 2/04/ EXELON CER 4,6MG/24h EXELON CER 9,MG/24h EXELON CPS.,MG EXELON CPS. 3MG EXELON CPS. 4,MG EXELON CPS. 6MG FLUTAMIDE TEVA*CPR 20MG L02BB0 FLUTAMIDE FOSTIMON 7 U.I. fl. G03GA04 UROFOLLITROPA FOZNOL 90 cpr 00 mg V03AE03 LANTANIO CARBONATO 90 2/04/ FOZNOL 90 cpr 70 mg V03AE03 LANTANIO CARBONATO 90 2/04/ FOZNOL 90 cpr 000 mg V03AE03 LANTANIO CARBONATO 90 2/04/ GALVUS cpr 0mg A0BH02 VIDAGLIPT 2/04/ GONAL F 7 U.I. fl. sc. G03GA0 FOLLITROPA ALFA GONAL F 7 U.I. fl. sc. G03GA0 FOLLITROPA ALFA GONAL F 0 U.I. Penna G03GA0 FOLLITROPA ALFA GONAL F 40 U.I. Penna G03GA0 FOLLITROPA ALFA GONAL F 900 U.I. Penna G03GA0 FOLLITROPA ALFA GONAL F 00 U.I. fl. sc. G03GA0 FOLLITROPA ALFA Pagina 2
3 DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' GONAPEPTYL DEPOT SIR. PRERIEMP. 3,7MG. L02AE04 TRIPTORELA GRANULOKE / ml. fl. L03AA02 FILGRASTIM GRANULOKE /0, ml. sir. L03AA02 FILGRASTIM TRON A SC IV FL 0MUI 0ML L03AB0 TERERONE ALFA - 2B TRON A SC IV PEN 8MUI+2KIT L03AB0 TERERONE ALFA - 2B TRON A SC IV FLC 8MUI L03AB0 TERERONE ALFA - 2B TRON A SC IV FL 2MUI 2,ML L03AB0 TERERONE ALFA - 2B TRON A SC IV PEN MUI+2KIT L03AB0 TERERONE ALFA - 2B VEGA cpr ril prol 3mg N0AX3 PALIPERIDONE 2/04/ VEGA cpr ril prol 6mg N0AX3 PALIPERIDONE 2/04/ VEGA cpr ril prol 9mg N0AX3 PALIPERIDONE 2/04/ IPSTYL mg fl + 2 ml solv H0CB03 LANREOTIDE ACETATO 2/04/ IPSTYL mg sir H0CB03 LANREOTIDE ACETATO 2/04/ IPSTYL 90mg sir H0CB03 LANREOTIDE ACETATO 2/04/ IPSTYL 20mg sir H0CB03 LANREOTIDE ACETATO 2/04/ JANUVIA CPR. 00 mg. A0BH0 SITAGLIPT KRYPTOCUR spray nasale 0 g H0CA0 GONADORELA 2/04/ LANTUS OPTISET SC PEN 00UI/ML. A0AE04 SULA GLARGE LANTUS SC FL. 0ML. 00UI/ML. A0AE04 SULA GLARGE LANTUS SC CART. 3ML.00UI/ML. A0AE04 SULA GLARGE LANTUS SOLOST. SC PEN. 00UI/ML. A0AE04 SULA GLARGE LEPONEX*CPR 2MG N0AH02 CLOZAPA LEPONEX*CPR 00MG N0AH02 CLOZAPA LEVEMIR FLEX PEN PEN 3 ML. 00UI/ML. A0AE0 SULA GLARGE LUVERIS 7 U.I. fl. G03GA07 LUTROPA ALFA LUVERIS 7 U.I. fl. G03GA07 LUTROPA ALFA MENOGON 7 U.I. fl. im. G03GA02 MENOTROPA MEROPUR 7 U.I. fl. sc. im. G03GA02 MENOTROPA altamente purificata MIMPARA mg cpr H0BX0 CACALCET CLORIDRATO 2/04/ MIMPARA mg cpr H0BX0 CACALCET CLORIDRATO 2/04/ MIMPARA 90 mg cpr H0BX0 CACALCET CLORIDRATO 2/04/ MIRCERA mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 0 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 7 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 00 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 20 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 0 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 200 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 20 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MIRCERA 3 mcg/0,3ml iv sc sir. B03XA03 METOSSIPOLIETILEGLICOLE EPOETA BETA 2/04/ MYELOSTIM 34 33,6 MIU fl. L03AA0 LENOGRASTIM NEORECORMON U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON.000 U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEORECORMON.000 U.I. sir. prer. sc. ev. B03XA0 ERITROPOIETA BETA NEULASTA 6 MG SIR 0,6ML SC C/P L03AA3 PEGFILGRASTIM ONGLYZA cpr riv mg A0BH03 SAXAGLIPT 2/04/ OVITRELLE 20 mcg/0,ml sir G03GA08 CORIOGONATROPA ALFA 2/04/ Pagina 3
4 DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' 0389 PEGASYS 3 mcg. sir L03AB PEG-TERFERONE ALFA-2A PEGASYS 80 mcg. Sir L03AB PEG-TERFERONE ALFA-2A PEGTRON 0 mcg. fl. sc. L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 0 mcg. penna L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 80 mcg. fl. sc. L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 80 mcg. penna L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 00 mcg. fl. sc. L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 00 mcg. penna L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 20 mcg. fl. sc. L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 20 mcg. Penna L03AB0 PEG-TERFERONE ALFA-2B PEGTRON 0 mcg. fl. sc. L03AB0 PEG-TERFERONE ALFA-2B PENTACARAT 0 mg im iv /aeros P0CX0 PENTAMIDA ISETIONATO 2/04/ PERGOVERIS 0UI/7UI sc fl G03GA FOLLITROPA ALFA/LUTROPA ALFA 0 2/04/ PLAVIX CPR. 7MG. B0AC04 CLOPIDROGREL PROGRAF cps 0, mg L04AD02 TACROLIMUS 2/04/ PROGRAF cps mg L04AD02 TACROLIMUS 2/04/ PROGRAF cps mg L04AD02 TACROLIMUS 2/04/ PROGRAF iv 0 fl mg/ ml L04AD02 TACROLIMUS 0 2/04/ PROVIGIL CPR 00MG. N06BA07 MODAFIL PUREGON 0 U.I. fl. sc. G03GA06 FOLLITROPA BETA PUREGON 00 U.I. fl. sc. G03GA06 FOLLITROPA BETA PUREGON 0 U.I. Cartucce G03GA06 FOLLITROPA BETA PUREGON 0 U.I. Cartucce G03GA06 FOLLITROPA BETA PUREGON 900 U.I. Cartucce G03GA06 FOLLITROPA BETA RANEXA cpr ril prol 37mg C0EB8 RANOLAZA 2/04/ RANEXA cpr ril prol 00mg C0EB8 RANOLAZA 2/04/ RANEXA cpr ril prol 70mg C0EB8 RANOLAZA 2/04/ RAPAMUNE os flc ml L04AA0 SIROLIMUS 2/04/ RAPAMUNE cpr 2 mg L04AA0 SIROLIMUS 2/04/ RAPAMUNE 00 cpr mg L04AA0 SIROLIMUS 00 2/04/ RATIOGRASTIM MUI 0, ml sir L03AA02 FILGRASTIM BIOSIMILARE 2/04/ REMYNIL CPR. RIV. 2MG. N06DA04 GALANTAMA REMYNIL CPR. RIV. 4MG. N06DA04 GALANTAMA REMYNIL CPR. RIV. 8MG. N06DA04 GALANTAMA RENVELA bs 2,4gr os V03AE02 SEVELAMER 2/04/ RENVELA 80 cpr 800mg V03AE02 SEVELAMER 80 2/04/ RETACRIT.000 UI /0,3 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0,6 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0,9 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0,4 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT.000 UI /0, ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0,6 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0,8 ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI / ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /0, ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT.000 UI /0,7ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RETACRIT UI /ml sir prer sc ev B03XA0 EPOETA ZETA BIOSIMILARE 2/04/ RISPER CPR. MG. N0AX08 RISPERIDONE RISPER CPR. 2MG. N0AX08 RISPERIDONE RISPER CPR. 3MG. N0AX08 RISPERIDONE RISPER CPR. 4MG. N0AX08 RISPERIDONE RISPER OS GTT. 00ML. MG./ML. N0AX08 RISPERIDONE Pagina 4
5 DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' ROFERON A SC SIR 3MUI/0,ML. L03AB04 TERERONE ALFA - 2A ROFERON A SC SIR 6MUI/0,ML. L03AB04 TERERONE ALFA - 2A ROFERON A SC SIR 9MUI/0,ML. L03AB04 TERERONE ALFA - 2A SANIFOL 0mg iv im fl V03AF03 CALCIO FOLATO 2/04/ SEROQUEL CPR. RIV. 2MG. N0AH04 QUETIAPA SEROQUEL 6 CPR. RIV. 2MG. N0AH04 QUETIAPA SEROQUEL CPR. RIV. 00MG. N0AH04 QUETIAPA SEROQUEL CPR. RIV. 200MG. N0AH04 QUETIAPA SEROQUEL CPR. RIV.0MG. N0AH04 QUETIAPA SEROQUEL CPR. RP 0MG N0AH04 QUETIAPA SEROQUEL CPR. RP 200MG N0AH04 QUETIAPA SEROQUEL CPR. RP 0MG N0AH04 QUETIAPA SEROQUEL CPR. RP 400MG N0AH04 QUETIAPA STALEVO 00 cpr. 0mg./2,mg./200mg N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE 00 2/04/ STALEVO 00 cpr. 7mg./8,7mg./200mg N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE 00 2/04/ STALEVO 00CPR. 00MG./2MG.200MG N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE STALEVO 00 cpr. 2mg./3,2mg./200mg N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE 00 2/04/ STALEVO 00 cpr. 0mg./37,2mg./200mg N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE 00 2/04/ STALEVO 00 cpr. 200mg./0mg./200mg N04BA03 LEVODOPA,CARBIDOPA,ENTACAPONE 00 2/04/ SUPREFACT DEPOT SIR 6,6MG. L02AE0 BUSERELA SUPREFACT DEPOT 3 MESI SIR 9,9MG. L02AE0 BUSERELA SUPREFACT IETT. F., ML. L02AE0 BUSERELA SUPREFACT SPRAY NASALE L02AE0 BUSERELA TANDEMACT 4 mg/ mg cpr A0BD06 PIOGLITAZONE+GLIMEPIRIDE 2/04/ TASMAR 00CPR RIV.00MG. N04BX0 TOLCAPONE TESTO ENANT fl 20 mg im G03BA03 TESTOSTERONE ENANTATO 2/04/ TEVAGRASTIM MUI 0, ml sir L03AA02 FILGRASTIM BIOSIMILARE 2/04/ TEVAGRASTIM 48MUI 0, ml sir L03AA02 FILGRASTIM BIOSIMILARE 2/04/ UROMITEXAN 400 mg iv fl 4 ml V03AF0 MESNA 2/04/ VESANOID 00 cps 0 mg L0XX4 TRETOA 00 2/04/ VICTOZA 6mg/ml 3 ml sc 2 penne A0BX07 LIRAGLUTIDE 2 2/04/ ZARZIO MUI 0, ml sir L03AA02 FILGRASTIM BIOSIMILARE 2/04/ ZARZIO 48MUI 0, ml sir L03AA02 FILGRASTIM BIOSIMILARE 2/04/ ZEFFIX cpr 00 mg J0AF0 LAMIVUDA 2/04/ ZEFFIX mg/ml os flc 240ml J0AF0 LAMIVUDA 2/04/ ZELDOX cps 20 mg N0AE04 ZIPRASIDONE 2/04/ ZELDOX cps 40 mg N0AE04 ZIPRASIDONE 2/04/ ZELDOX cps mg N0AE04 ZIPRASIDONE 2/04/ ZEMPLAR cps mcg H0BX02 PARACALCITOLO 2/04/ ZEMPLAR cps 2 mcg H0BX02 PARACALCITOLO 2/04/ ZEMPLAR fl iv mcg/ml H0BX02 PARACALCITOLO 2/04/ ZOLADEX SC SIR 3,6MG. R.P. L02AE03 GOSERELA ZOLADEX SC SIR 0,8MG. R.P. L02AE03 GOSERELA ZYPREXA CPR. RIV. 2,MG. N0AH03 OLANZAPA ZYPREXA CPR. RIV. MG. N0AH03 OLANZAPA ZYPREXA CPR. RIV.0,MG. N0AH03 OLANZAPA ZYPREXA VELOTAB CPR. MG. N0AH03 OLANZAPA ZYPREXA VELOTAB CPR. 0MG. N0AH03 OLANZAPA Pagina
Allegato 1 - Farmaci sottoposti a piano terapeutico LEGENDA PT GENERICO. piano terapeutico con template generico. PT SPECIFICO + nome principio attivo
Allegato 1 - Farmaci sottoposti a piano terapeutico LEGENDA PT GENERICO PT SPECIFICO + nome principio attivo PT AIFA CONTINUITA' TERAPEUTICA H-T piano terapeutico con template generico piano terapeutico
DPC 20151120 040321010 ONDANSETRONE SETOFILM*6FILMS ORODISP 4MG A04AA01 040321046 ONDANSETRONE SETOFILM*6FILMS ORODISP 8MG A04AA01
MINSAN Principio Attivo DESCRIZIONE ATC/CODICE COMPLEMENTA RE 040321010 ONDANSETRONE SETOFILM*6FILMS ORODISP 4MG A04AA01 040321046 ONDANSETRONE SETOFILM*6FILMS ORODISP 8MG A04AA01 027612074 ONDANSETRONE
Manufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
November 2015. The Impact of Biosimilar Competition
November 2015 The Impact of Competition Introduction This document sets out to describe the effects on price, volume and share following the arrival and presence of biosimilar competition in the European
Prontuario Terapeutico Ospedaliero
Prontuario Terapeutico Ospedaliero Pagina 1 di 56 Impostazione Il presente Prontuario Terapeutico Ospedaliero, suddiviso per gruppi terapeutici, comprende farmaci anche a brevetto scaduto, dei quali è
ALLEGATO 5/A TECNICO
ALLEGATO 5/A TECNICO parte lasciata alla compilazione delle Ditte offerenti 1 2 3 4 5 1 A01AB Miconazolo os 2% 80g tb 2 A01AC Diflucortolone + josamicina os sol. muc.10ml flc 3 A01AD Cloromicetina digluconato
Approximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
PRODUCT INN REFERENCE AUTHORIZATION Omnitrope
PRODUCT INN REFERENCE AUTHORIZATION Omnitrope Genotropin 12/04/2006 somatropin Valtropin (W/D) Humatrope 24/04/2006 Abseamed Binocrit Epoetina alfa hexal Retacrit Silapo Biograstim Filgrastim ratiopharm
LISTADO DE MEDICAMENTOS CON SUSTANCIAS INCLUIDAS EN RESOLUCION DOPAJE VIGENTE
LISTADO DE MEDICAMENTOS CON SUSTANCIAS INCLUIDAS EN RESOLUCION DOPAJE VIGENTE Medicamentos con sustancias descritas en la Resolución de 18 de diciembre de 2014 de la Presidencia del Consejo Superior de
Burlington Scripts Vs. Current local purchase plan. Current Copays
Introduction: Burlington Scripts is a voluntary prescription drug program that is available to eligible Employees, Retirees and their Dependents of the Town of Burlington, MA. For your convenience, a list
Prontuario Terapeutico Aziendale - ASL TO4 Aggiornato a MAGGIO 2014
Prontuario Terapeutico Aziendale - ASL TO4 Aggiornato a MAGGIO 2014 ATC 7AC1D01 A01AB09 A01AD11 PEROSSIDO DI IDROGENO 3% MICONAZOLO DICLOFENAC IDROSSIETILPIRROLIDINA ACQUA OSSIGENATA FU 10VOL 250CC (3%
Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
An Industry Perspective
AIPPI World IP Congress 2014 Workshop Pharma 2 Biosimilar pharmaceutical products An Industry Perspective September 16, 2014 Masahisa Yamaguchi, PhD Department Manager Intellectual Property Dept. Chugai
Let s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014
Let s Talk About Meters and Meds Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014 How to monitor diabetes control: Hemoglobin A 1 C, or just A 1
Lessons for the United States: Biosimilar Market Development Worldwide
Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar
Active Clinical Trials
Active Clinical Trials 1. Genentech Efalizumab Protocol No. ACD4230g Title: A Phase II/III, Randomized, Open-Label, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab
2014 Valley Baptist Medicare D Formulary Step Therapy Criteria
2014 Valley Baptist Medicare D Formulary Step Therapy Products Affected ACTONEL TAB Last Updated 11/1/2014 Requires a trial of alendronate. 1 APLENZIN TAB Patient must have tried bupropion SR or bupropion
PL CE LIVE December 2011 Long Guide
This handout accompanies the related articles published in December 2011 ~ Volume 27 ~ Number 12 following PL CE LIVE December 2011 Long Guide CARDIOLOGY You ll start hearing lots more about the comparisons
HMO and PPO Updates May 2013- Commercial Results
HMO and PPO Updates May 2013- Commercial Results ELIQUIS Non Triple Tier Formular y 4th Tier Applicable Traditional Alternatives warfarin, Xarelto, Pradaxa TAMIFLU - EXPANDED INDICATION 2 No 2 No No None
Helstu breytingar á verðskrá ágúst 2011
Helstu breytingar á verðskrá ágúst 2011 Norrænt vheiti breytts lyfs Form Styrkur Magn ATC flokku Gamalt gildi Nýtt gildi Af undanþágulista 001574 Enalapril Mylan töflur 2,5 mg 50 stk C09AA02 1 Af viðmiðunarverðskrá
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
TRANSPARENCY COMMITTEE OPINION. 18 July 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2007 ENANTONE SR 3.75 mg, sustained-release powder and solvent for suspension for injection (SC or IM ) (CIP:
Medicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
Making Clinical Sense of Diabetes Medications. Types of Diabetes. Pathophysiology. Beta Cell Function & Glucagon
Making Clinical Sense of Diabetes Medications Kathy Reily, RD, CDE Prince William Hospital Diabetes Program Coordinator Virginia Dietetic Association April 4, 2011 Types of Diabetes Type 1 DM = Beta Cell
SHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
PL CE LIVE December 2011 Forum
December 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor Pharmacist s Letter/Prescriber s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited
Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
Male Hypogonadism. Hypogonadism is characterised by impaired testicular function, which may affect spermatogenesis and/or testosterone synthesis.
L APPROCCIO MEDICO AL PAZIENTE AZOOSPERMICO Marco Rossato Università degli Studi di Padova Dipartimento di Medicina - DIMED Clinica Medica 3 Direttore: prof. Roberto VETTOR Male Hypogonadism Hypogonadism
2015 Formulary Addendum Notice of Change
2015 Formulary Addendum Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. WellCare Extra (PDP) This is a listing of the changes that have occurred in our formulary. Please
0,15% collutorio BENZIDAMINA. confezione 4 A01AD02 CLORIDRATO COLLUTORIO circa 120 ml 4.987 3.167 0 200 0 0 0 1.500 0 120 0 0 0 0
FORMA n ATC PRINCIPIO ATTIVO FARMACEUTICA DOSAGGIO Q.TA' SASSARI OLBIA ORISTANO NUORO LANUSEI SANLURI CARB. CAGLIARI totale pht dpc pht dpc pht dpc pht dpc pht dpc dpc dpc dpc 1 A01AB03 CLOREXIDINA COLLUTORIO
ALLEGATO 1 Prezzi. Prezzo in. ATC Principio Attivo
ALLEGATO 1 Prezzi ATC Principio Attivo C07AB04 ACEBUTOLOLO 30 CPR.400 MG 7,50 M01AB16 ACECLOFENAC 30 BUST. 100 MG 8,09 M01AB16 ACECLOFENAC 40 CPR. 100 MG 10,80 J05AB01 ACICLOVIR 25 compresse 200 mg 11,29
Promotion of Prescription Drugs to Consumers and Providers, 2001 2010
to Consumers and Providers, 2001 2010 Rachel Kornfield 1, Julie Donohue 2,3, Ernst R. Berndt 4,5, G. Caleb Alexander 1,6,7,8 * 1 Section of General Internal Medicine, Department of Medicine, University
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the
PRONTUARIO FARMACI CLASSE C COLLUTTORIO CLOREXIDINA 0,2% FLAC.250ML CLASSE C CLASSE C CLASSE C CLASSE A CLASSE A CLASSE A
PRONTUARIO FARMACI A - APPARATO GASTROINTESTINALE E METABOLISMO A01 - stomatologici A01AB - antimicrobici per trattamento orale locale A01AB09 MICONAZOLO NITRATO 543 A01AD - altri farmaci per il trattamento
UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES
UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
supplement 18 PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 1VIAL
supplement 18 NOM DOSAGE FORME NR ST LABORATOIRE PAYS D'ORIGINE ACTEMRA 80MG/4ML 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 218156/09 * CHUGAI PHARMA MANUFACTURING CO LTD FOR F.HOFFMANN-LA ROCHE LTD -
How To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
Type 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
Guidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
Diabetes Medications. Minal Patel, PharmD, BCPS
Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore
Colonoscopy and Flexible Sigmoidoscopy advice for Diabetics
Colonoscopy and Flexible Sigmoidoscopy adice for Diabetics Information for patients Guidelines for Diet and Tablet controlled diabetes: pages 2-4 Guidelines for Insulin controlled diabetes: pages 5-8 Diet
Preferred Drug List Updates Effective: Jan. 1, 2016
Molina Healthcare regularly reviews and updates the Preferred Drug List (PDL). Items may be added, removed or changed. Below is the list of updates made to the PDL this quarter. Some items require a prior
Cara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
Part D Event (PDE) Cost Information. Barbara Frank, M.S., M.P.H. Director of Workshops, Outreach, & Research University of Minnesota
Part D Event (PDE) Cost Information Barbara Frank, M.S., M.P.H. Director of Workshops, Outreach, & Research University of Minnesota Part D Event (PDE) Cost Information Researchers cannot determine true
Clinical Summary of Pediatric Metabolic AERS Reports. Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA
Clinical Summary of Pediatric Metabolic AERS Reports Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA 1 Clinical Summary of Pediatric Metabolic AERS Reports: Atypical Antipsychotics n=100 reports;
Access to medicines - time for a progressive model
Access to medicines - time for a progressive model Richard Bergström, EFPIA Director General 1 A question of solidarity The sense of fairness and equity between Member States is being eroded. And without
Autism Spectrum Disorder Formulation & Resource Guide
Autism Spectrum Disorder Formulation & Resource Guide Autism Spectrum Disorder Formulation & Resource Guide Knowledge Changes Everything: Quality. Innovation. Experience. Since 1974. 2015 College Pharmacy
ZANTAC 150 mg cpr rivestite con film - scatola 20 cpr. ZANTAC 300 mg cpr rivestite con film - scatola 20 cpr
ATC Lotto Descrizione Lotto Risultato procedura AIC Nome Commerciale Farmaco CIG P.A. A02BA02 4 A02BA02 5 A02BA02 6 A02BA02 7 A02BA02 8 RANITIDINA CLORIDRATO COMPRESSE RIVESTITE 150 RANITIDINA CLORIDRATO
QUANTITY LIMITS TABLE
S TABLE / TABLA DE ABILIFY ARIPIPRAZOLE ORAL SOLUTION 900 ML IN 30 DAYS ABILIFY DISCMELT 10 MG ARIPIPRAZOLE TAB RAPDIS 30 TABS IN 30 DAYS ABILIFY DISCMELT 15 MG ARIPIPRAZOLE TAB RAPDIS 60 TABS IN 30 DAYS
DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
PATIENT ASSISTANCE PROGRAMS
PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
UnitedHealthcare Group Medicare Advantage (PPO)
Your Plan Explained UnitedHealthcare Group Medicare Advantage (PPO) UHEX11MP3230855_001 Y0066_100616_09113 Your Medicare. This brochure explains your Medicare Advantage plan, a type of health plan also
Antihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
Monthly Copays. Union Copays Crestor 20MG - Tier 2,10% Eliquis 5mg - Tier 3, 20% Non-Union Copays Crestor 20MG - Tier 2, $25
Introduction: MCSMeds is an international mail order option for eligible Employees, Retirees and Dependents of Muncie Community Schools. Your list of qualified maintenance medications is on the reverse.
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
How To Get A Generic Drug From A Pharmacy Benefit Manager
Requesting an Exception to the Formulary You can ask Network Health Insurance Corporation to make an exception to our coverage rules. Generally, we will only approve your request for an exception if alternative
MEDICATION(S) SUBJECT TO STEP THERAPY
ACE/ARB COMBO AZOR 5-20 MG TABLET, AZOR 5-40 MG TABLET, BENICAR HCT, MICARDIS HCT, TARKA, TEKTURNA HCT, TELMISARTAN-HYDROCHLOROTHIAZID, TRIBENZOR Claims for formulary step 2 ACE Inhibitor combination products
PRONTUARIO TERAPEUTICO AZIENDALE A.O. LEGNANO
A.T.C. PRINCIPIO ATTIVO DOSAGGIO TOTALE della forma farmaceutica FORMA FARMACEUTICA A- APPARATO GASTROINTESTINALE A01AB03 clorexidina 200MG/ML 150 ML SOLUZ. MUCOSA ORALE A01AB09 miconazolo 2% GEL ORALE
PTP indice medicinale
PTP indice medicinale ODIE SIA MEDIINALE AT5 PA 2900006 ABELET EV 100 MG 20 ML 10FL + J02AA01 AMFOTERIINA B * H-Osp1 AGHI 62800005 AESISTEM 14 PR 20MG+12.5MG 09BA02 ENALAPRIL+IDROLOROTIAZIDE A 450001 AETILISTEINA
Doncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible
PRONTUARIO TERAPEUTICO CLASSIFICAZIONE PER A.T.C.
PRONTUARIO TERAPEUTICO CLASSIFICAZIONE PER A.T.C. Prontuario Terapeutico RSA/RAF A APPARATO GASTROINTESTINALE E METABOLISMO A02 FARMACI PER DISTURBI CORRELATI ALL'ACIDITA' A02AD ASSOCIAZIONI FRA COMPOSTI
25 mg QD-TID @ meals w/1st bite of. food, titrate Q 4 8 weeks; adjust based on 1 postprandial glucose; 100 mg TID max
Table Selected Non-Insulin Antihyperglycemic Agents Class Drug (Brand) Dosing Comments -Glucosidase inhibitors Acarbose a (Precose) 25 mg QD-TID @ meals w/1st bite of MOA: Enzyme inhibitor, delays hydrolysis
Medicines Used to Treat Type 2 Diabetes
Goodman Diabetes Service Medicines Used to Treat Type 2 Diabetes People who have type 2 diabetes may need to take medicine to help lower their blood glucose, in addition to being active & choosing healthy
Advance IV Therapy Module. Example 1. 3mg. 3mg min = 45
Advance IV Therapy Module Eample A patient is to receive Lidocaine at 3mg/. Supplied is a one liter bag of D 5 W containing Lidocaine 4g. Calculate the infusion rate in ml/. First, identify the doctor
Monthly Copays. Medications must be tried for 30 days before ordering through Aspire Indiana CanaRx.
Introduction: Aspire Indiana CanaRx is an international mail order option for eligible Employees and their Dependents of Aspire Indiana, Inc. For your convenience, a list of eligible medications is located
_003452024 VALONTAN*10CPR RIV 100MG A FARMACO DA BANCO (OTC) 7,09 D _003452048 VALONTAN*BB 4CPR RIV 25MG A FARMACO DA BANCO (OTC) 5,49 D _003710011
Allegato 9 Minsan Descrizione Prodotto Tipo Prodotto Prezzo IMS 31/05/2013 TPRICETTABD _000367058 TISANA KELEMATA*ERBE OS 80G A FARMACO DA BANCO (OTC) 8,38 D _000367072 TISANA KELEMATA*20BUST 1,3G A FARMACO
How To Write An Annual Formulary Bulletin For The Health Trust
Area Drug & Therapeutics Committee NHS Ayrshire & Arran Formulary Bulletin January 2009 Edition In this issue: Salbutamol inhaler (Salbulin MDPI Novolizer) Ertapenem infusion (Invanz ) Thalidomide capsules
Diabetes in Primary Care course MCQ Answers 2016
Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE
we have to keep up. Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Entity Activity Financial Consideration Comments
Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Entity Activity Financial Consideration Comments Novo Nordisk Speaker/Consultant Speaker Fees/Honoraria Sanofi-Aventis Speaker/Consultant Speaker
State of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing
Bobby Jindal GOVERNOR State of Louisiana Department of Health and Hospitals Bureau of Health Services Financing Kathy H. Kliebert SECRETARY The purpose of this memo is to advise you that effective September
Immune-response and adverse reactions: PRCA case example. Nicole Casadevall
Immune-response and adverse reactions: PRCA case example Nicole Casadevall Recombinant human erythropoietin (rhuepo) 1985: EPO gene cloned 1986: first clinical trials in CKD 1988: rhepo is licensed for
New and Emerging Diabetes Medications. What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE
New and Emerging Diabetes Medications What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE Objectives 1) Describe the clinical indications on select emerging novel diabetes
The following book is required for purchase prior to the beginning of the semester:
Dear Student: As a faculty member of the Johns Hopkins University School of Nursing, we are pleased to welcome you to the School. In preparation for a key nursing course, Principles and Applications in
Acarbose INITIAL: 25 mg PO TID ($45) Miglitol INITIAL: 25 mg PO TID ($145)
PL Detail-Document #310601 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Drugs for Type 2
Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines
Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines Survey Finds Private Sector Negotiations Provide Both Savings and Choice, Making Government Interference Unnecessary
DIABETES EDUCATION. *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS
DIABETES EDUCATION *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS ACTION: Sulfonylureas stimulate the pancreas to make more insulin (pancreas
Elenco dei brevetti non coperti da certificato complementare di protezione
ITA EP N TRADUZIONE EP TITOLO PRINCIPIO ATTIVO MARCHIO DEPOSITO SCADENZA EP633784 EP652766 EP656775 RM2002B047565 MI2008B025368 RM1998B048516 EP656780 MI1997B025294 EP658118 MI2002B023364 EP591710 RM1996B048988
INSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
Critical Care Calculations Study Guide
Example #1 Your 65 kg patient has dopamine ordered at 6 mcg/kg/min. The IV has 400 mg of dopamine in 250 ml. What IV rate is correct? 1. Always determine the dose of medication per ml (Drug Concentration)
Extra Value Drug List. *
List. * Brand Diabetes Levemir 100 units/ml Vial 10mL $122.29 Levemir FlexPen 100 units/ml 15mL $203.03 NovoLog 100 units/ml Vial 10mL $116.84 NovoLog FlexPen Syringe 15mL $222.41 NovoLog 100 units/ml
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS The aim of the Diabetes level 2 service is to provide a high quality service for safe initiation and optimization of injectable therapy within GP networks.
Educational Objectives. Type 2 Diabetes: a progressive condition. Insulin Delivery Devices. Insulin we may wait too long
Educational Objectives Insulin Delivery Devices James Bennett RPh, FACA, CDE Director of Clinical Services at James Bennett Apothecary Corinth Mississippi After viewing this program, participants should
Lareb Intensive Monitoring
Lareb Intensive Monitoring May 14, 2014 UMC pharmacovigilance course Linda Härmark, PharmD, PhD Head Reporting department www.lareb.nl Outline Why intensive monitoring? Lareb Intensive Monitoring Pregabalin
Saxagliptin (Onglyza) for type 2 diabetes
Saxagliptin (Onglyza) for type 2 diabetes This Medicine Update is for people who are taking, or thinking about taking, saxagliptin. Summary Saxagliptin (brand name Onglyza) is a tablet that can be used
PATIENT APPLICATION FORM INSTRUCTIONS
INSTRUCTIONS The Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. To apply online, access program information
QuarterWatch: 2010 Quarter 3
QuarterWatch: 2010 Quarter 3 Monitoring MedWatch Reports May 19, 2011 New Signals for Liraglutide, Quetiapine and Varenicline Executive Summary In this issue we examine a signal for liraglutide (VICTOZA),
TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS. Friday, August 16, 13
TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS 1 Heather Healy, FNP-BC Martha Shelver, CS, ACNP-BC Saint Alphonsus Regional Medical Center 2 OBJECTIVES 3 Review the current management algorithms
Letter to Shareholders
Letter to Shareholders Robert A. Bradway, Chairman and Chief Executive Officer, Amgen Inc. Dear Shareholders, 2014 was an extraordinary year for Amgen financially, scientifically and organizationally.
Management of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
Overview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
Indication: Posology: Indication: Posology:
Maklumat tambahan indikasi untuk upload pada laman web Year 2014 Products Approved For Additional Indication (DCA 275 9 Mei 2014) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 Trajenta Duo 2.5mg/500mg Film-Coated
ATC/DDD Classification
ATC/DDD Classification ATC/DDD Classification (Temporary) The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology
November 5, 2015 Quarterly pharmacy formulary change notice
November 5, 2015 Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at the 2nd Quarter Pharmacy and Therapeutics (P&T) Committee meetings
DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION
ACTEMRA (toclizumab) 10/21/13 ADASUVE (loxapine aerosol powder breath activated) 01/24/14 ADDAMEL N INJ (Trace Min (CR-CU-F-FE-I-MN-MO-SE-ZN) INJ) 05/20/13 ADYNOVATE (Antihemophilic Factor Recomb Pegylated
Illinois Valley Community College Nursing Program Math Questions
Illinois Valley Community College Nursing Program Math Questions 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. How many mg of the antibiotic Penicillin would you prepare for a child who weighs
PHARMACOLOGY UPDATE: BOOMER DRUGS
PHARMACOLOGY UPDATE: BOOMER DRUGS Sandra Brownstein, PharmD Evercare Clinical Pharmacy Director West Region Objectives: Review the new drugs that have recently been approved by the FDA Determine the role
Fordøyelsesorganer og stoffskifte Alimentary tract and metabolism
Fordøyelsesorganer og stoffskifte Alimentary tract and metabolism A01 A02 A03 A04 A05 A06 A07 A08 A09 A10 A11 A12 A16 Munn- og tannmidler (utelatt) Stomatological preparations (not included) Midler mot